Sonnet BioTherapeutics Analyst Ratings
Sonnet BioTherapeutics Analyst Ratings
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a with a price target of $0.00 to $6.70. The current price Sonnet BioTherapeutics (SONN) is trading at is $0.28, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/23/2023 | 2317.9% | EF Hutton | → $6.7 | Assumes | → Buy |
| 08/16/2023 | 4230.57% | Chardan Capital | $14 → $12 | Maintains | Buy |
| 06/26/2023 | 2317.9% | EF Hutton | → $6.7 | Reiterates | Buy → Buy |
| 05/25/2023 | 2317.9% | EF Hutton | → $6.7 | Assumes | → Buy |
| 05/11/2023 | 4952.33% | Chardan Capital | $17 → $14 | Maintains | Buy |
| 04/19/2023 | 2317.9% | EF Hutton | → $6.7 | Reiterates | → Buy |
| 04/19/2023 | 6034.97% | Chardan Capital | $22 → $17 | Maintains | Buy |
| 02/15/2023 | 2317.9% | EF Hutton | → $6.7 | Reiterates | → Buy |
| 12/19/2022 | 2317.9% | EF Hutton | → $6.7 | Initiates Coverage On | → Buy |
| 09/22/2022 | 7839.37% | Chardan Capital | $2 → $22 | Maintains | Buy |
| 08/16/2022 | 621.76% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 02/09/2022 | 621.76% | BTIG | $5 → $2 | Maintains | Buy |
| 12/20/2021 | 802.2% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 12/16/2021 | 621.76% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 09/15/2021 | 1704.4% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 09/04/2020 | 2787.04% | Chardan Capital | $7 → $8 | Maintains | Buy |
| 06/05/2020 | 2426.16% | Chardan Capital | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023/08/23 | 2317.9% | EF Hutton | →$6.7 | 假設 | →購買 |
| 08/16/2023 | 4230.57% | 查爾丹資本 | $14→$12 | 維護 | 買 |
| 2023/06/26 | 2317.9% | EF Hutton | →$6.7 | 重申 | 購買→購買 |
| 2023年05月25日 | 2317.9% | EF Hutton | →$6.7 | 假設 | →購買 |
| 2023年05月11日 | 4952.33% | 查爾丹資本 | $17→$14 | 維護 | 買 |
| 04/19/2023 | 2317.9% | EF Hutton | →$6.7 | 重申 | →購買 |
| 04/19/2023 | 6034.97% | 查爾丹資本 | $22→$17 | 維護 | 買 |
| 02/15/2023 | 2317.9% | EF Hutton | →$6.7 | 重申 | →購買 |
| 2022年12月19日 | 2317.9% | EF Hutton | →$6.7 | 開始承保 | →購買 |
| 09/22/2022 | 7839.37% | 查爾丹資本 | $2→$22 | 維護 | 買 |
| 08/16/2022 | 621.76% | 查爾丹資本 | $2.5→$2 | 維護 | 買 |
| 02/09/2022 | 621.76% | BTIG | $5→$2 | 維護 | 買 |
| 12/20/2021 | 802.2% | 查爾丹資本 | $8→$2.5 | 維護 | 買 |
| 12/16/2021 | 621.76% | HC Wainwright公司 | →$2 | 開始承保 | →購買 |
| 2021/09/15 | 1704.4% | BTIG | →$5 | 開始承保 | →購買 |
| 09/04/2020 | 2787.04% | 查爾丹資本 | $7→$8 | 維護 | 買 |
| 06/05/2020 | 2426.16% | 查爾丹資本 | →$7 | 開始承保 | →購買 |
What is the target price for Sonnet BioTherapeutics (SONN)?
Sonnet BioTreateutics(SONN)的目標價格是多少？
The latest price target for Sonnet BioTherapeutics (NASDAQ: SONN) was reported by EF Hutton on August 23, 2023. The analyst firm set a price target for $6.70 expecting SONN to rise to within 12 months (a possible 2317.90% upside). 10 analyst firms have reported ratings in the last year.
EF Hutton於2023年8月23日報道了十四網生物治療公司(納斯達克：SONN)的最新目標價。這家分析公司將目標價定為6.7美元，預計SUNN將在12個月內上漲(漲幅可能為2317.90)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Sonnet BioTherapeutics (SONN)?
Sonnet BioTreateutics(SONN)的最新分析師評級是多少？
The latest analyst rating for Sonnet BioTherapeutics (NASDAQ: SONN) was provided by EF Hutton, and Sonnet BioTherapeutics their buy rating.
十四網生物治療公司(納斯達克代碼：SONN)的最新分析師評級由EF Hutton提供，十四網生物治療公司的評級為買入。
When is the next analyst rating going to be posted or updated for Sonnet BioTherapeutics (SONN)?
Sonnet BioTreeutics(SONN)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonnet BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonnet BioTherapeutics was filed on August 23, 2023 so you should expect the next rating to be made available sometime around August 23, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Sonnet BioTreateutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Sonnet BioTreateutics的上一次評級是在2023年8月23日提交的，所以你應該預計下一次評級將在2024年8月23日左右提供。
Is the Analyst Rating Sonnet BioTherapeutics (SONN) correct?
分析師對Sonnet BioTreateutics(SONN)的評級正確嗎？
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a with a price target of $0.00 to $6.70. The current price Sonnet BioTherapeutics (SONN) is trading at is $0.28, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Sonnet BioTreateutics(SONN)評級為A，目標價在0.00美元至6.70美元之間。目前Sonnet BioTreateutics(SUNN)的交易價格為0.28美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。